Aditya Birla Sunlife Life Pharma & Healthcare IDCW Reinvest Direct Plan
SIP amount
Min. ₹500
Lumpsum amount
Min. ₹1,000

Aditya Birla Sunlife Life Pharma & Healthcare IDCW Reinvest Direct Plan

NAV
₹21.6400
+0.23%
(23 Feb)
AUM
649 Cr
TER
1.03%
Risk
Very High Risk
Insights
Net Asset Value (NAV) is above its 200 days moving average
Total Expense Ratio (TER) is in the top 25% of comparable funds
In beta. Send feedback here.
Compare with other fund
1Y
+98.2%
+98.2%
+79.5%
+79.5%
+54.9%
3Y
+41.0%
+41.0%
+46.8%
+46.8%
+18.3%
5Y
+27.1%
+27.1%
+38.8%
+38.8%
NA
ALL
+12.6%
+12.6%
+20.6%
+20.6%
+23.6%
VOL
19.7%
19.7%
20.1%
20.1%
17.5%
TER
1.0%
1.0%
0.8%
0.8%
1.0%
AUM
₹1,432 Cr
₹1,432 Cr
₹1,636 Cr
₹1,636 Cr
₹649 Cr
INFO
0.64
0.64
1.03
1.03
1.35
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
Aditya Birla Sunlife Life Pharma & Healthcare IDCW Reinvest (DR)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 31st Jan
Top holdings
Sun Pharmaceuticals Industries Ltd
14.5%
Cipla Ltd
8.1%
Torrent Pharmaceuticals Ltd
7.6%
Aurobindo Pharma Ltd
7.5%
Apollo Hospitals Enterprise Ltd
7.2%
Fortis Healthcare Ltd
4.8%
Lupin Ltd
3.8%
Zydus Lifesciences Ltd
3.7%
Sanofi India Ltd
3.6%
J.B. Chemicals & Pharmaceuticals Ltd
3.2%
Top industry exposure
Healthcare
95.3%
Financial Services
1.2%
Basic Materials
0.5%
Other information
Minimum SIP
₹500
Minimum lumpsum
₹1,000
Additional lumpsum
₹1,000
Portfolio turnover
31%
Lock-in period
-
Exit load
• 1% for redemption within 30 days
Fund objective
The scheme provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. The Scheme does not guarantee/indicate any returns. There can be no assurance that the schemes’ objectives will be achieved.
Fund manager(s)
Dhaval Shah
Dhaval Joshi

FAQs